Mogrify

Mogrify has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.

In a collaboration with Sangamo, Mogrif’s cell conversion technology will be applied to generate regulatory T cells (Tregs) from pluripotent stem cells and embryonic stem cells. Sangamo aims to apply its ZFP gene engineering technology to Tregs as allogeneic cell therapies to treat inflammatory and autoimmune diseases.

Timeline

October 14, 2019

Mogrify raises $3.7M in seed capital, appoints Dr. Darrin M. Disley, OBE as CEO, launches the Mogrify V2 and Epimogrify V1 platforms, and is raising an additional $16 million USD in the initial close of its Series A funding.

October 14, 2019

Mogrify raises a $16,000,000 series A round from Ahren Innovation Capital.

October 2019

Mogrify raises a $16,000,000 series A round from Ahren Innovation Capital, Parkwalk Advisors, University of Bristol Enterprise Fund and 24Haymarket.